Communiqués de presse

Emerald Health Therapeutics Announces Stock Option Grant
VANCOUVER, August 3, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that it has issued an aggregate of 3,800,000 stock options to employees, consultants and directors at an exercise price of $0.21 per common share for a period of five
Août 3, 2020
Formats Additionnels
Emerald Health Therapeutics to Host 2019 Fourth Quarter and Year End Financial Results Conference Call on Thursday, May 14, 2020 at 10:30 AM ET
VANCOUVER, May 8, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that, further to its news release on April 29th, Emerald will report audited financial results for the fourth quarter and year ended December 31, 2019 after the market
Mai 8, 2020
Formats Additionnels
Emerald Health Therapeutics to Launch Rapid Onset Nanoemulsion Cannabinoid & Terpene Product Line, Providing Consumers with Enhanced Immediacy and Control
Unique product line uses advanced technology to improve cannabinoid absorption by roughly 65% to provide more predictable dosing, onset and effects, as well as discreetness and value, of THC and CBD products for medicinal and adult-use users VANCOUVER, April 29, 2020 – Emerald Health Therapeutics,
Avr. 29, 2020
Formats Additionnels
Emerald Health Therapeutics’ Joint Venture, Pure Sunfarms, Reports Positive Operating and Financial Growth in 2019, with Significant EBITDA Performance of $54.1 Million
VANCOUVER, March 31, 2020 – Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has provided audited financial results for the fourth quarter and year of 2019 for its British Columbia-based joint venture, Pure Sunfarms (PSF). Financial Data All comparable figures are for the
Mars 31, 2020
Formats Additionnels
Affichage 1 - 10 sur 13